Trial Profile
A randomized, double-blind, multi-center, phase II fixed dose study of multiple doses of ipilimumab (MDX-010) monotherapy in patients with previously treated unresectable stage III or IV melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 13 Nov 2007 Status changed from in progress to completed.
- 15 Jan 2007 Status change
- 31 Mar 2006 New trial record.